A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III)

Proctor, Stephen J.; Mackie, M. J.; Dawson, Audrey A.; White, Jo; Prescott, R. J.; Lucraft, Helen; Angus, Brian; Jackson, Graham; Lennard, Anne; Hepplestone, A; Taylor, Pennie

doi:10.1016/s0959-8049(02)00006-0

Cited by 48 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This led to the development of the SNLG prognostic index in 1985, and although not published until 1991, it was used prospectively to define risk status as 'standard' or 'high' from 1987 (Proctor et al, 1991). It became the defining element of the SNLG-HD III randomised study for high-risk patients, which ran from 1988 to 1998 (Proctor et al, 2002). As a result, adolescents in the region who developed HL were prospectively assessed as described above, hence the early emergence of the risk -related strategy for the over 16 years cohort described here.…”

Section: Discussionmentioning

confidence: 99%

“…Among older patients with HL, it has been repeatedly demonstrated that the survival data in populationbased studies are poorer than those from clinical trials (Kennedy et al, 1985;Appleton et al, 1995;Clarke et al, 2001;Proctor et al, 2002;Jarrett et al, 2005). This effect is likely to be due, at least in part, to the exclusion of frailer elderly individuals from clinical NLPHD (n=7) cHL (n=48) NLPHD ( (Hudson et al, 1993(Hudson et al, , 2004Hutchinson et al, 1998;Friedmann et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

“…The additional value of such an approach is that fertility might be better preserved in male patients using ABVD alone. Certainly eight-drug schedules, such as PVACEBOP, are associated with inevitable male sterility, although female fertility in the under 40 years patients on SNLG-HD III (Proctor et al, 2002) has been well preserved. We would argue that the new study approaches should be linked to assessment of existing prognostic indices to further assess their role in defining risk.…”

Section: Discussionmentioning

confidence: 99%

“…The Northern Region Lymphoma Group (NRLG) collected data prospectively on all patients diagnosed with HL in the Northern region of England, as previously described (Taylor et al, 1998;Proctor et al, 2002). In addition, the Northern Region Young Person's Malignancy Registry (NRYPMR) collects data at presentation from all patients, aged p25 years diagnosed with a malignant disease in the same geographical area (Cotterill et al, 2000).…”

Section: Methodsmentioning

confidence: 99%

“…High-risk patients Patients identified as high risk were eligible for the SNLG-HD III trial protocol (Proctor et al, 2002), which involved treatment with three consecutive 28-day cycles of an eight-drug regimen (PVACEBOP: procarbazine, vinblastine, dox- Absolute lymphocyte count is entered as a score = 1 1.0 -1.5×10 9 l -1 = 2 1.5-2.0×10 9 l -1 = 3 >2.0×10 9 l -1 = 4…”

Section: Treatment Strategymentioning

confidence: 99%

See 4 more Smart Citations

Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents

et al. 2007

Self Cite

View full text Add to dashboard Cite

The aim was to assess outcome in a population-based cohort of adolescents with Hodgkin's lymphoma (HL) diagnosed in the UK's northern region over a 10-year period. Among a population of 3.09 million, 55 of 676 patients (8%) diagnosed with HL were aged 13 -19. Seven had nodular lymphocyte-predominant HL, 48 classical HL (cHL). Of the latter, 36 were X16 years. Application of the Scottish and Newcastle Lymphoma Group (SNLG) prognostic index meant 21 patients were considered high risk (index X0.5). They received PVACEBOP multi-agent chemotherapy as primary therapy. Standard risk patients (SNLG index o0.5) were treated with standard ChlVPP or ABVD chemotherapy7radiotherapy. Scottish and Newcastle Lymphoma Group indexing is not valid for patients under 16. Twelve patients therefore received UKCCSG protocols (n ¼ 8), ABVD plus radiotherapy (n ¼ 2), or PVACEBOP (n ¼ 2). Forty-six patients with cHL (96%) achieved complete remission. Seven patients relapsed but all entered complete remission after salvage therapy. Five patients died: three of HL, one in an accident and one of disseminated varicella complicating cystic fibrosis. Five-and 10-year overall survival was 93 and 86%, respectively; disease-specific survival was 95 and 92%. The data suggest that older adolescents with high-risk HL require intensive protocols as primary therapy to secure optimal outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Treatment Strategymentioning

confidence: 99%

See 3 more Smart Citations

Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

Hodgkin's Disease and Adolescents: The Lost Tribe?

Windebank¹

2005

Cancer and the Adolescent

View full text Add to dashboard Cite

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

et al. 2014

View full text Add to dashboard Cite

on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell TransplantationThe optimal treatment strategy with the use of hematopoietic stem cell transplantation (HSCT) for relapsed and refractory Hodgkin lymphoma (HL) remains unclear. We performed a retrospective analysis using registry data from the Japanese Society for Hematopoietic Cell Transplantation. Adult patients with HL who underwent a first autologous or a first allogeneic HSCT between 2002 and 2009 were included. Patients who underwent HSCT in first complete remission (CR) were excluded. Autologous and allogeneic HSCT were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at 3 years (3yOS) was 70%, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. OS was favorable even in patients who underwent autologous HSCT in disease status other than CR. For allogeneic HSCT, 3yOS was 43%, and sex and PS at HSCT were prognostic factors. Disease status at HSCT, previous autologous HSCT, and conditioning intensity did not affect OS. Moreover, graft-versus-host disease did not affect progression-free survival or relapse/progression rate. A first allogeneic HSCT without a previous autologous HSCT was performed in 40 patients. 3yOS was 45%, and was significantly inferior to that in patients who underwent their first autologous HSCT. This result was retained after the correction by the different patient characteristics according to the type of HSCT. In conclusion, autologous HSCT is effective in prolonging survival in patients with relapsed and refractory HL. Allogeneic HSCT might be beneficial even to relapsed HL after autologous HSCT, although establishing the role of allogeneic HSCT remains a challenge.

show abstract

A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III)

Cited by 48 publications

References 18 publications

Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents

Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents

Hodgkin's Disease and Adolescents: The Lost Tribe?

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Contact Info

Product

Resources

About